Table 9 Knockdown of TPX2 enhances the sensitiivty of MHCC97-H cells to antitumor drugs, TKIs and chemotherapies.

From: TPX2 enhances the transcription factor activation of PXR and enhances the resistance of hepatocellular carcinoma cells to antitumor drugs

Antitumor drugs

Control

siTPX2

IC50 values (μmol/L)

sorafenib

1.16 (0.95–1.31)

0.47 (0.31–0.74)

lenvatinib

1.07 (0.74–1.22)

0.50 (0.39–0.70)

regorafenib

0.99 (0.89–1.24)

0.75 (0.69–1.11)

cabozantinib

0.76 (0.66–0.97)

0.26 (0.15–0.46)

doxorubicin

0.20 (0.05–0.36)

0.06 (0.05–0.09)

paclitaxel

12.67 (6.5–17.3) (nmol/L)

4.20 (4.06–4.35) (nmol/L)

etoposide

0.25 (0.15–0.50)

0.10 (0.09–0.13)

irinotecan

0.52 (0.29–0.88)

0.16 (0.12–0.20)

  1. IC50 values (μmol/L) were shown as median values (95% confidence interval)
Back to article page